These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 23545663)

  • 21. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
    Gwon HC; Hahn JY; Park KW; Song YB; Chae IH; Lim DS; Han KR; Choi JH; Choi SH; Kang HJ; Koo BK; Ahn T; Yoon JH; Jeong MH; Hong TJ; Chung WY; Choi YJ; Hur SH; Kwon HM; Jeon DW; Kim BO; Park SH; Lee NH; Jeon HK; Jang Y; Kim HS
    Circulation; 2012 Jan; 125(3):505-13. PubMed ID: 22179532
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical impact of dual antiplatelet therapy use in patients following everolimus-eluting stent implantation: insights from the SEEDS study.
    Zhang YJ; Zhao YL; Xu B; Han YL; Li B; Liu Q; Su X; Pang S; Lu SZ; Guo XF; Yang YJ
    Chin Med J (Engl); 2015 Mar; 128(6):714-20. PubMed ID: 25758261
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of six versus 12 months of dual antiplatelet therapy in patients with drug-eluting stent implantation after risk stratification with the residual SYNTAX score: Results from a secondary analysis of the I-LOVE-IT 2 trial.
    Qiu M; Li Y; Li J; Xu K; Jing Q; Dong S; Jin Z; Zhao P; Xu B; Han Y
    Catheter Cardiovasc Interv; 2017 Mar; 89(S1):565-573. PubMed ID: 28211603
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 6-Month Versus 12-Month Dual-Antiplatelet Therapy Following Long Everolimus-Eluting Stent Implantation: The IVUS-XPL Randomized Clinical Trial.
    Hong SJ; Shin DH; Kim JS; Kim BK; Ko YG; Choi D; Her AY; Kim YH; Jang Y; Hong MK;
    JACC Cardiovasc Interv; 2016 Jul; 9(14):1438-46. PubMed ID: 27212028
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimal Duration of Dual Antiplatelet Therapy after Drug-Eluting Stents: Meta-Analysis of Randomized Trials.
    Abo-Salem E; Alsidawi S; Jamali H; Effat M; Helmy T
    Cardiovasc Ther; 2015 Oct; 33(5):253-63. PubMed ID: 26010419
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
    Bittl JA; Baber U; Bradley SM; Wijeysundera DN
    J Am Coll Cardiol; 2016 Sep; 68(10):1116-39. PubMed ID: 27036919
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial.
    Colombo A; Chieffo A; Frasheri A; Garbo R; Masotti-Centol M; Salvatella N; Oteo Dominguez JF; Steffanon L; Tarantini G; Presbitero P; Menozzi A; Pucci E; Mauri J; Cesana BM; Giustino G; Sardella G
    J Am Coll Cardiol; 2014 Nov 18-25; 64(20):2086-97. PubMed ID: 25236346
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: Meta-analysis of randomized controlled trials.
    Fei Y; Tsoi MF; Cheung TT; Cheung BM
    Int J Cardiol; 2016 Oct; 220():895-900. PubMed ID: 27400191
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
    Mauri L; Kereiakes DJ; Yeh RW; Driscoll-Shempp P; Cutlip DE; Steg PG; Normand SL; Braunwald E; Wiviott SD; Cohen DJ; Holmes DR; Krucoff MW; Hermiller J; Dauerman HL; Simon DI; Kandzari DE; Garratt KN; Lee DP; Pow TK; Ver Lee P; Rinaldi MJ; Massaro JM;
    N Engl J Med; 2014 Dec; 371(23):2155-66. PubMed ID: 25399658
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-world reasons and outcomes for 1-month versus longer dual antiplatelet therapy strategies with a polymer-free BIOLIMUS A9-coated stent.
    Gallone G; D'Ascenzo F; Boccuzzi G; Cortese B; Di Biasi M; Omedè P; Capodanno D; Cerrato E; Vicinelli P; Infantino V; Poli A; Ugo F; Conrotto F; Grigis G; Varbella F; Latini RA; D'Urbano M; Montabone A; Senatore G; Ferrara E; D'Amico M; De Ferrari GM; Ielasi A
    Catheter Cardiovasc Interv; 2020 Sep; 96(3):E248-E256. PubMed ID: 32012453
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Duration of dual antiplatelet therapy after implantation of the first-generation and second-generation drug-eluting stents.
    Yu X; Chen F; He J; Gao Y; Wu C; Luo Y; Zhang X; Zhang Y; Ren X; Lv S
    Coron Artery Dis; 2013 May; 24(3):217-23. PubMed ID: 23425771
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial.
    Kim BK; Hong SJ; Cho YH; Yun KH; Kim YH; Suh Y; Cho JY; Her AY; Cho S; Jeon DW; Yoo SY; Cho DK; Hong BK; Kwon H; Ahn CM; Shin DH; Nam CM; Kim JS; Ko YG; Choi D; Hong MK; Jang Y;
    JAMA; 2020 Jun; 323(23):2407-2416. PubMed ID: 32543684
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of Dual Antiplatelet Therapy Beyond 1 Year on Clinical Outcomes of Patients With Stent Fracture or Peri-Stent Contrast Staining After Sirolimus-Eluting Stent Implantation.
    Fuku Y; Kadota K; Amano H; Kubo S; Otsuru S; Habara S; Tada T; Tanaka H; Goto T
    Circ J; 2017 Dec; 82(1):211-217. PubMed ID: 28855451
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.
    Yeh RW; Secemsky EA; Kereiakes DJ; Normand SL; Gershlick AH; Cohen DJ; Spertus JA; Steg PG; Cutlip DE; Rinaldi MJ; Camenzind E; Wijns W; Apruzzese PK; Song Y; Massaro JM; Mauri L;
    JAMA; 2016 Apr; 315(16):1735-49. PubMed ID: 27022822
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11 473 patients.
    Palmerini T; Della Riva D; Benedetto U; Bacchi Reggiani L; Feres F; Abizaid A; Gilard M; Morice MC; Valgimigli M; Hong MK; Kim BK; Jang Y; Kim HS; Park KW; Colombo A; Chieffo A; Sangiorgi D; Biondi-Zoccai G; Généreux P; Angelini GD; Pufulete M; White J; Bhatt DL; Stone GW
    Eur Heart J; 2017 Apr; 38(14):1034-1043. PubMed ID: 28110296
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimal duration of dual antiplatelet therapy after second-generation drug-eluting stent implantation in patients with diabetes: The SECURITY (Second-Generation Drug-Eluting Stent Implantation Followed By Six- Versus Twelve-Month Dual Antiplatelet Therapy)-diabetes substudy.
    Tarantini G; Nai Fovino L; Tellaroli P; Chieffo A; Barioli A; Menozzi A; Frasheri A; Garbo R; Masotti-Centol M; Salvatella N; Dominguez JF; Steffanon L; Presbitero P; Pucci E; Fraccaro C; Mauri J; Giustino G; Sardella G; Colombo A
    Int J Cardiol; 2016 Mar; 207():168-76. PubMed ID: 26803236
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dual Antiplatelet Therapy for 6 Versus 18 Months After Biodegradable Polymer Drug-Eluting Stent Implantation.
    Nakamura M; Iijima R; Ako J; Shinke T; Okada H; Ito Y; Ando K; Anzai H; Tanaka H; Ueda Y; Takiuchi S; Nishida Y; Ohira H; Kawaguchi K; Kadotani M; Niinuma H; Omiya K; Morita T; Zen K; Yasaka Y; Inoue K; Ishiwata S; Ochiai M; Hamasaki T; Yokoi H;
    JACC Cardiovasc Interv; 2017 Jun; 10(12):1189-1198. PubMed ID: 28641838
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation).
    Kim BK; Hong MK; Shin DH; Nam CM; Kim JS; Ko YG; Choi D; Kang TS; Park BE; Kang WC; Lee SH; Yoon JH; Hong BK; Kwon HM; Jang Y;
    J Am Coll Cardiol; 2012 Oct; 60(15):1340-8. PubMed ID: 22999717
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Real-World Dual Antiplatelet Therapy Following Polymer-Free Sirolimus-Eluting Stent Implantations to Treat Coronary Artery Disease.
    Krackhardt F; Waliszewski M; Kočka V; Toušek P; Janek B; Hudec M; Lozano F; Roman KG; Del Blanco BG; Mauri J; Heang TM; Ahn TH; Jeong MH; Herberger D; Tomulic V; Levy G; Sebagh L; Rischner J; Pansieri M
    Cardiovasc Drugs Ther; 2020 Jun; 34(3):335-344. PubMed ID: 32212061
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and Safety of Dual Antiplatelet Therapy After Complex PCI.
    Giustino G; Chieffo A; Palmerini T; Valgimigli M; Feres F; Abizaid A; Costa RA; Hong MK; Kim BK; Jang Y; Kim HS; Park KW; Gilard M; Morice MC; Sawaya F; Sardella G; Genereux P; Redfors B; Leon MB; Bhatt DL; Stone GW; Colombo A
    J Am Coll Cardiol; 2016 Oct; 68(17):1851-1864. PubMed ID: 27595509
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.